Jarskog LF[au] - Search Results

Year	Number of Results
1997	3
1999	1
2000	5
2001	2
2002	1
2003	1
2004	4
2005	3
2006	6
2007	5
2008	2
2009	4
2010	6
2011	5
2012	5
2013	5
2014	6
2015	2
2016	2
2017	4
2018	6
2019	13
2020	11
2021	6
2022	2
2023	2

1

Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia.

Fernandez HH, Stamler D, Davis MD, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Woods SW, Bega D, LeDoux MS, Shprecher DR, Anderson KE. Fernandez HH, et al. Among authors: jarskog lf. J Neurol Neurosurg Psychiatry. 2019 Dec;90(12):1317-1323. doi: 10.1136/jnnp-2018-319918. Epub 2019 Jul 10. J Neurol Neurosurg Psychiatry. 2019. PMID: 31296586 Free PMC article. Clinical Trial.

2

Schizophrenia: when clozapine fails.

Miyamoto S, Jarskog LF, Fleischhacker WW. Miyamoto S, et al. Among authors: jarskog lf. Curr Opin Psychiatry. 2015 May;28(3):243-8. doi: 10.1097/YCO.0000000000000159. Curr Opin Psychiatry. 2015. PMID: 25768082 Review.

3

Response to Rosenfeld.

Jarskog LF, Stroup TS. Jarskog LF, et al. Am J Psychiatry. 2014 Jan;171(1):119-20. doi: 10.1176/appi.ajp.2013.13091193r. Am J Psychiatry. 2014. PMID: 24399433 No abstract available.

4

Effects of oxytocin on empathy, introspective accuracy, and social symptoms in schizophrenia: A 12-week twice-daily randomized controlled trial.

Halverson T, Jarskog LF, Pedersen C, Penn D. Halverson T, et al. Among authors: jarskog lf. Schizophr Res. 2019 Feb;204:178-182. doi: 10.1016/j.schres.2018.09.013. Epub 2018 Sep 20. Schizophr Res. 2019. PMID: 30243853 Free PMC article. Clinical Trial.

5

Neuroprotection in schizophrenia.

Jarskog LF, Lieberman JA. Jarskog LF, et al. J Clin Psychiatry. 2006 Sep;67(9):e09. doi: 10.4088/jcp.0906e09. J Clin Psychiatry. 2006. PMID: 17081076

6

Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection.

Lieberman JA, Malaspina D, Jarskog LF. Lieberman JA, et al. Among authors: jarskog lf. CNS Spectr. 2006 Apr;11(4):suppl 1-13; quiz suppl 14-5. CNS Spectr. 2006. PMID: 16641837

7

Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia.

Lieberman JA, Perkins DO, Jarskog LF. Lieberman JA, et al. Among authors: jarskog lf. CNS Spectr. 2007 Mar;12(3 Suppl 4):1-13; quiz 14. doi: 10.1017/s1092852900025906. CNS Spectr. 2007. PMID: 17329984

8

Schizophrenia: new pathological insights and therapies.

Jarskog LF, Miyamoto S, Lieberman JA. Jarskog LF, et al. Annu Rev Med. 2007;58:49-61. doi: 10.1146/annurev.med.58.060904.084114. Annu Rev Med. 2007. PMID: 16903799 Review.

9

New therapeutic approaches for treatment-resistant schizophrenia: a look to the future.

Miyamoto S, Jarskog LF, Fleischhacker WW. Miyamoto S, et al. Among authors: jarskog lf. J Psychiatr Res. 2014 Nov;58:1-6. doi: 10.1016/j.jpsychires.2014.07.001. Epub 2014 Jul 8. J Psychiatr Res. 2014. PMID: 25070124 Review.

10

Apoptosis in schizophrenia: pathophysiologic and therapeutic considerations.

Jarskog LF. Jarskog LF. Curr Opin Psychiatry. 2006 May;19(3):307-12. doi: 10.1097/01.yco.0000218603.25346.8f. Curr Opin Psychiatry. 2006. PMID: 16612218 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

93 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

93 results

Results by year